Related references
Note: Only part of the references are listed.Development Times, Clinical Testing, Postmarket Follow-up, and Safety Risks for the New Drugs Approved by the US Food and Drug Administration The Class of 2008
Thomas J. Moore et al.
JAMA INTERNAL MEDICINE (2014)
Legal Foundations of Adaptive Licensing
K. Oye et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval
H-G Eichler et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
What principles should govern the use of managed entry agreements?
Marianne Klemp et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2011)
A flexible blueprint for the future of drug development
Richard Barker
LANCET (2010)
Access with Evidence Development The US Experience
Penny E. Mohr et al.
PHARMACOECONOMICS (2010)
Web-based toolkit to facilitate European collaboration on evidence generation on promising health technologies
Fabienne Quentin et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2009)
Practical tools and methods for health technology assessment in Europe: Structures, methodologies, and tools developed by the European network for Health Technology Assessment, EUnetHTA
Finn Borlum Kristensen et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2009)
A common policy framework for evidence generation on promising health technologies
Cedric Carbonneil et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2009)
Coverage options for promising technologies: Medicare's 'coverage with evidence development'
Sean R. Tunis et al.
HEALTH AFFAIRS (2006)
Medicare's coverage of colorectal cancer drugs: A case study in evidence development and policy
Tanisha Carino et al.
HEALTH AFFAIRS (2006)
Share Paper
